Pharmacokinetics and Pharmacodynamics with Extended Dosing of CC-486 in Patients with Hematologic Malignancies

• Eric Laille ,

  Contributed equally to this work with: Eric Laille, Tao Shi

  * E-mail: elaille@celgene.com

  ¶‡ These authors are co-lead authors on this work.

  Affiliation Celgene Corporation, Summit, New Jersey, United States of America

  ⨯
• Tao Shi ,

  Contributed equally to this work with: Eric Laille, Tao Shi

  ¶‡ These authors are co-lead authors on this work.

  Affiliation Celgene Corporation, Summit, New Jersey, United States of America

  ⨯
• Guillermo Garcia-Manero,

  Affiliation Department of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, Texas, United States of America

  ⨯
• Christopher R. Cogle,

  Affiliation Division of Hematology/Oncology, University of Florida, Gainesville, Florida, United States of America

  ⨯
• Steven D. Gore,

  Affiliation Yale Cancer Center, New Haven, Connecticut, United States of America

  ⨯
• Joel Hetzer,

  Affiliation Celgene Corporation, Summit, New Jersey, United States of America

  ⨯
• Keshava Kumar,

  Affiliation Celgene Corporation, Summit, New Jersey, United States of America

  ⨯
• Barry Skikne,

  Affiliation Celgene Corporation, Summit, New Jersey, United States of America

  ⨯
• Kyle J. MacBeth

  Affiliation Celgene Corporation, Summit, New Jersey, United States of America

  ⨯